Table 2 Primary and secondary objectives and endpoints
Objective | Endpoint(s)a |
Primary objective | |
 To explore the airway anti-inflammatory effect of tezepelumab | Change from baseline to week 28 in airway submucosal inflammatory cells (eosinophils, neutrophils, T cells and mast cells) from bronchoscopic biopsies |
Secondary objectives | |
 To explore the effect of tezepelumab on RBM thickening | Change from baseline to week 28 in RBM thickness |
 To explore the effect of tezepelumab on airway epithelial integrity | Change from baseline to week 28 in airway epithelial integrity |
 To explore the airway anti-inflammatory effect of tezepelumab across the spectrum of T2 status | Change from baseline to week 28 in airway submucosal inflammatory cells (eosinophils, neutrophils, T cells and mast cells) of bronchoscopic biopsies in patients across the T2 spectrum |